Cite
SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
MLA
“SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients.” Renal & Urology News, Dec. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.730154493&authtype=sso&custid=ns315887.
APA
SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients. (2022, December 15). Renal & Urology News.
Chicago
Renal & Urology News. 2022. “SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients,” December 15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.730154493&authtype=sso&custid=ns315887.